BLTE BELITE BIO INC

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4, 2025. Details of the presentation are as follows:

  • 10:30 am ET, corporate presentation

Webcast Link Instructions

A webcast of the presentation will be available on the conference website at . The replay will be accessible for 90 days following the presentation date.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on , , , and  or visit us at .

Media and Investor Relations Contact:

Jennifer Wu

Julie Fallon



EN
29/10/2025

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Off...

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has priced an underwritten public offering of 2,272,727 American Depositary Shares (“ADSs”), each representing one of its ordinary shares, at a public offering price of $154.00 per ADS. The C...

December 2, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Proposed Underwritten Public Offering of American...

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addit...

December 1, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

New Hope for People Living with a Disease Once Deemed Untreatable: Bel...

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was ...

December 1, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a...

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exerciseCompleted pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025China’s NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on...

November 10, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quar...

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, November 10...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch